NLS Drug Development Pharma

Xellia Pharmaceuticals (‘Xellia’), a specialty pharmaceutical company focusing on providing important anti-infective treatments against

The Committee for Medicinal Products for Human Use (CHMP) today issued a positive opinion for the use of Victoza® (liraglutide) in adults with type 2 diabetes and moderate renal impairment. Once the European Commission approves the label expansion, physicians in the European Union will be able to prescribe Victoza®, a once-daily human glucagon-like peptide-1 (GLP-1) analogue, to […]

Norwegian company Bionor Pharma is in talks with the U.S. Federal Drug Administration (FDA) about a possible collaboration on a study to test a trial HIV vaccine early next year.  Bionor reported strong results in one of its tests of vaccine Vacc-4x in combination with the drug Revlimid. Vacc-4x works by activating the body’s immune system to kill […]

BerGenBio AS, a Norwegian oncology biopharmaceutical company, announced Wednesday that the US Food and Drug Administration (FDA) granted orphan-drug designation for BGB324 for treatment of acute myeloid leukemia (AML). Earlier this month BerGenBio announced that the first patient was dosed in its multi-center Phase 1b trial of BGB324, a selective inhibitor of Axl, in patients […]

AstraZeneca officials are feeling positive about the future, with enough drugs in production to fuel double-digit submissions and approvals by 2017, reaffirming its promise to grow sales by 75 percent.  The company has 14 Phase III drugs that will account for eight-to-ten approvals over the next two years. Leading the way is the company’s revitalized […]

While sales of AstraZeneca’s blood-thinner Brilinta have been growing, the company has started a preclinical development program on a potential Brilinta antidote, now known as MEDI2452. If it works, the antidote could quickly reverse the effects of the blood thinner in an emergency, such as a person having a major bleeding episode. Doctors would not […]